Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • In Brief
  • Published:

Systemic lupus erythematosus

Long-term anifrolumab safe in SLE

Nature Reviews Rheumatology volume 19, page 64 (2023)Cite this article

Subjects

In a long-term extension study of the TULIP trials, assessing the safety and tolerability of the type I interferon receptor antagonist anifrolumab in patients with systemic lupus erythematosus, the benefit-to-risk profile of anifrolumab remained favourable after 3 years of treatment. The exposure-adjusted incidence rate (EAIR) of serious adverse events was comparable between the anifrolumab group and placebo group (8.5 versus 11.2), as were the EAIRs of non-opportunistic serious infections, malignancy and major acute cardiovascular events. The exposure-adjusted event rate of COVID-19-related adverse events was higher in the anifrolumab group than in the placebo group (15.5 versus 9.8), but no COVID-19-related adverse events occurred in fully vaccinated individuals.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

References

Original article

Download references

Author information

Authors and Affiliations

  1. Nature Reviews Rheumatology http://www.nature.com/nrrheum/

    Jessica McHugh

Authors
  1. Jessica McHugh
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Jessica McHugh.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

McHugh, J. Long-term anifrolumab safe in SLE. Nat Rev Rheumatol 19, 64 (2023). https://doi.org/10.1038/s41584-022-00902-4

Download citation

  • Published:

  • Version of record:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41584-022-00902-4

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing